Skip to content
Screener

Altimmune ALT Pre-Tax Income

Pre-Tax Income at other companies

Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%
Merck & Co. logo
Merck & Co.MRK
-$683M-114%
Delcath Systems logo
Delcath SystemsDCTH
$3.16M-1.4%
Wave Life Sciences logo
Wave Life SciencesWVE
-$69.36M-37.4%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$65.54M-1,101%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$45.93M+44.9%

Other financials

Income statement

See full
Revenue$26.0K+420%
Operating income-$24.2M-11.1%
Net income-$22.6M-15.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$97.6M+98.7%
Total debt$34.8M+14,092%
Total equity$284.0M+99.8%
Total assets$335.6M+113%

Cash flow

See full
Operating cash flow-$20.9M-24.4%
CapEx$21.0K
Free cash flow-$21.0M

Valuation

See full
Market cap$593.15M+116%
Enterprise value$530.27M+402%

Profitability

See full
Operating margin-230,461%-82,087pp
Net margin-214,861%-76,057pp
FCF margin-17,806.8%-110,030pp

Returns & leverage

See full
Return on equity-42.7%-8.7pp
Debt / equity0.1×+0.1×
Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Altimmune’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326190-26-000040
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Interest income2,9011,545
Other income (expense), net(152)15
Total other income (expense), net1,6811,559
Net loss before income taxes(22,563)(20,256)
Income tax expense (benefit)(681)
Net loss(22,563)(19,575)
Other comprehensive income — unrealized loss on short-term investments(296)(30)
Comprehensive loss$(22,859)$(19,605)

Item 1. Financial Statements

FAQ

What is Altimmune's pre-tax income?
Altimmune (ALT) reported pre-tax income of -$22.56M in Q1 2026.
How has Altimmune's pre-tax income changed year-over-year?
Altimmune's pre-tax income decreased by 11.4% year-over-year, from -$20.26M to -$22.56M.
What is the long-term trend for Altimmune's pre-tax income?
Over 2 years (2021 to 2025), Altimmune's pre-tax income has grown at a -4.4% compound annual growth rate (CAGR), from -$97.09M to -$88.77M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Altimmune's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude